Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study

Overview of attention for article published in BMC Nephrology, April 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (85th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

policy: 2 policy sources
twitter: 10 X users

facebook: 2 Facebook pages
wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 82 Dimensions

Readers on

mendeley: 134 Mendeley

Summary Policy documents X Facebook Wikipedia Dimensions citations

So far, Altmetric has seen 2 policy documents that reference this research output.

ravulizumab

Cited by Canadian Agency for Drugs and Technologies in Health on 07 Jun 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Ravulizumab for treating atypical haemolytic uraemic syndrome : Committee papers

Cited by National Institute for Health and Care Excellence on 04 Jun 2021

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.